Status update: DECODE recruitment finalized! This is the second dose finding study PanACEA completed in 2022. We continue to work together with LegoChemBio to get those long anticipated delpazolid exposure-response results.

clinicaltrials.gov/ct2/show/NCT04…

Well done CAPRISA team for randomising your 1⃣ participant into Harvest trial. Huge achievement with all that is going on in hospitals. One step closer to knowing whether high dose rifampicin improves outcomes of TB meningitis. Richard Lessells S Marais K Naidoo & team 👏

Ziekenhuisapotheker en klinisch farmacoloog Rob Aarnoutse is met ingang van 16 november 2020 benoemd tot hoogleraar aan het Radboudumc. Lees meer over de benoeming in ons nieuwsbericht.radboudumc.nl/nieuws/2021/ro…

publications.edctp.org/annual-report-… You can now read the EDCTP Annual Report of 2019. It features the PanACEA phase 2 study of BTZ-043, a promising chemical entity for TB treatment #TB LMU Klinikum München EDCTP

First publication from the project of EDCTP Career Development Fellow Dr Marion Sumari-de Boer (KCRI, Tanzania): 'Effect of reminder cues and tailored feedback on adherence to antiretroviral drug treatment among HIV-positive individuals in the Kilimanjaro region, Tanzania'

We are honoured that our Annual Meeting is covered by local and national Tanzanian news. Asante sana! @NIMRHQS NIMR Mbeya Faustine Ndugulile Wizara ya Afya Tanzania 🇹🇿 EDCTP TB Trials @ Uni of St Andrews Infection St Andrews youtu.be/pQ63HsU-7ac

EDCTP-funded (EUR 4.8 million) PROTID RCT study (Preventive treatment of latent #tuberculosis infection in patients with #diabetes mellitus) is coordinated by Dr Reinout van Crevel Radboudumc Netherlands with partners from New Zealand, Tanzania, Uganda, and the United Kingdom.

PRESS RELEASE: BTZ-043 is tested on TB patients for the first time in Phase II study by PanACEA, funded by EDCTP BMBF: 'If BTZ043 proves to be safe and effective in the current study, this would be a major step in the development of a new drug' bit.ly/2E7Vudi

PanACEA 2:The new promising #tuberculosis drug BTZ-043 has been administered to patients for the first time in Cape Town, South Africa. The study is funded by EDCTP and the German Federal Ministry of Education and Research bit.ly/2EgbwBL PanACEA BMBF

Now in production our radio series on advanced #HIV disease 📻
Trial participants, Sr Alice, Dr Mo & @thsseb shine a light 🔦 on late diagnosis, opportunistic infections, diagnostic & therapeutic advances.
Listen up 🎧 in the lead up to #WorldAIDSDay Infectious Diseases Institute, Makerere University London School of Hygiene & Tropical Medicine David

radboudumc.nl/en/vacancies/7…

radboudumc.nl/en/vacancies/7…

We are looking for a PhD student for this amazing project on latent TB and DM in Africa!

Lindsey te Brake presenting PK results from PanACEA HIGHRIF1. Increasing 14-day bactericidal activity to 50mg/kg rifampicin but increasing numbers of tolerability AEs. Elin Svensson #TBPK

Novel drug development paths, estimands, and data-driven stratified medicine - great times at the INTERTB meeting! Patrick Phillips PanACEA #stoptb

FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis. Learn more: bit.ly/2MZj81i

Infection St Andrews is glad to see the commitment to the task of planning new #tuberculosis treatment trials PanACEA ! twitter.com/derekjsloan/st…

Lindsey te Brake kicks off the PanACEA Annual Meeting 2018 in Cape Town with a presentation on the ongoing PanACEA HR1 trial Lindsey te Brake

Modelling to figure out how we should best use a new TB-drug #StopTB #Pharmacometrics PreDiCT-TB
academic.oup.com/jac/article/41…

Inspiring discussions about capacity development and ongoing and future plans by the PanACEA Executive Group today in Amsterdam.